{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T22:04:34Z","timestamp":1776117874050,"version":"3.50.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nutr. Diabetes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background\/objectives<\/jats:title>\n                    <jats:p>Diabetic nephropathy (DN) is a prevalent microvascular diabetic complication that is not totally unveiled. In this study, we considered GAS6, AXL, GAS6-AS1, and GAS6-DT as possible early diagnostic biomarkers of DN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Subjects\/methods<\/jats:title>\n                    <jats:p>The study included 70 patients with normoalbuminuria type 2 diabetes (DM), 70 patients with microalbuminuria type 2 diabetes (DN), and 60 apparently healthy controls. Fasting plasma glucose, glycosylated hemoglobin, and plasma creatinine were enzymatically assayed. Albuminuria, plasma GAS6, and AXL levels were determined using ELISA. Long non-coding RNAs GAS6-AS1 and GAS6-DT levels were determined in blood using qRT-PCR. Several bioinformatics databases were employed to suggest interactions with the studied biomolecules.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      GAS6 and AXL were downregulated in DM\u2009+\u2009DN compared to controls, being the lowest in DN (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). GAS6-DT was upregulated in DM\u2009+\u2009DN compared to controls, being the highest in DN (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). GAS6-AS1 was higher in DN than in controls (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.013). GAS6, AXL, and GAS6-DT showed fair-to-moderate significant correlations with HbA1c, fasting glucose, creatinine, and albuminuria. ROC curves showed remarkable diagnostic power of GAS6, AXL, and GAS6-DT (AUC\u2009=\u20090.72\u20131.0), but not GAS6-AS1, in DN and DM, with moderate-to-excellent agreement with conventional diagnostics.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The current findings emphasize the significance of the GAS6\/AXL pathway in DM and DN progression, where GAS6, AXL, and GAS6-DT showed significantly altered values in DM, and further in DN, with notable diagnostic power for both diseases. To date, this is the first study confirming the diagnostic power of AXL and GAS6-DT in DN and DM. Future studies are warranted to evaluate therapeutically targeting this pathway to manage DN.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41387-025-00400-y","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T15:41:19Z","timestamp":1763048479000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Association of GAS6, AXL, and GAS6-AS lncRNAs with nephropathy in Egyptian patients with type 2 diabetes mellitus: a case\u2013control observational study"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8925-9702","authenticated-orcid":false,"given":"Tarek Kamal","family":"Motawi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina","family":"Sabry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4490-8793","authenticated-orcid":false,"given":"Nancy Mamdouh","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9746-5335","authenticated-orcid":false,"given":"Nancy Nabil","family":"Shahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"400_CR1","unstructured":"International Diabetes Federation. IDF Diabetes Atlas [Internet]. 10th ed. Diabetes Research and Clinical Practice. Brussels, Belgium; 2021. https:\/\/www.diabetesatlas.org."},{"key":"400_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/genes15010123","volume":"15","author":"LA Bravo-V\u00e1zquez","year":"2024","unstructured":"Bravo-V\u00e1zquez LA, Paul S, Col\u00edn-Jurado MG, M\u00e1rquez-Gallardo LD, Casta\u00f1\u00f3n-Cort\u00e9s LG, Banerjee A, et al. Exploring the therapeutic significance of microRNAs and lncRNAs in kidney diseases. Genes. 2024;15:1\u201325.","journal-title":"Genes"},{"key":"400_CR3","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s11255-022-03354-7","volume":"55","author":"SM Swaminathan","year":"2023","unstructured":"Swaminathan SM, Rao IR, Shenoy SV, Prabhu AR, Mohan PB, Rangaswamy D, et al. Novel biomarkers for prognosticating diabetic kidney disease progression. Int Urol Nephrol. 2023;55:913\u201328.","journal-title":"Int Urol Nephrol"},{"key":"400_CR4","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.7150\/thno.80435","volume":"13","author":"X Jiang","year":"2023","unstructured":"Jiang X, Liu X, Qu X, Zhu P, Wo F, Xu X, et al. Integration of metabolomics and peptidomics reveals distinct molecular landscape of human diabetic kidney disease. Theranostics. 2023;13:3188\u2013203.","journal-title":"Theranostics"},{"key":"400_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-60336-4","volume":"10","author":"D Deli\u0107","year":"2020","unstructured":"Deli\u0107 D, Wiech F, Urquhart R, Gabrielyan O, Rieber K, Rolser M, et al. Linagliptin and telmisartan induced effects on renal and urinary exosomal miRNA expression in rats with 5\/6 nephrectomy. Sci Rep. 2020;10:3373.","journal-title":"Sci Rep"},{"key":"400_CR6","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1007\/s00125-018-4567-5","volume":"61","author":"HM Colhoun","year":"2018","unstructured":"Colhoun HM, Marcovecchio ML. Biomarkers of diabetic kidney disease. Diabetologia. 2018;61:996\u20131011.","journal-title":"Diabetologia"},{"key":"400_CR7","doi-asserted-by":"crossref","unstructured":"Zhang J, Zhang R, Wang Y, Li H, Han Q, Wu Y, et al. The level of serum albumin is associated with renal prognosis in patients with diabetic nephropathy. J Diabetes Res. 2019;2019:7825804.","DOI":"10.1155\/2019\/7825804"},{"key":"400_CR8","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1080\/10641963.2017.1288739","volume":"39","author":"W Li","year":"2017","unstructured":"Li W, Wang J, Ge L, Shan J, Zhang C, Liu J. Growth arrest-specific protein 6 (Gas6) as a noninvasive biomarker for early detection of diabetic nephropathy. Clin Exp Hypertens. 2017;39:382\u20137.","journal-title":"Clin Exp Hypertens"},{"key":"400_CR9","doi-asserted-by":"publisher","first-page":"332","DOI":"10.46912\/jbrcp.159","volume":"3","author":"A Emedoh","year":"2020","unstructured":"Emedoh A, Okani C, Abbiyesuku F. The pattern of plasma Gas-6 elevation among type II diabetes mellitus patients in relation to microalbuminuria using urinary albumin creatinine ratio. J Biomed Res Clin Pract. 2020;3:332\u20139.","journal-title":"J Biomed Res Clin Pract"},{"key":"400_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.123482","volume":"3","author":"F Zhong","year":"2018","unstructured":"Zhong F, Chen Z, Zhang L, Xie Y, Nair V, Ju W, et al. Tyro3 is a podocyte protective factor in glomerular disease. JCI Insight. 2018;3:1\u201318.","journal-title":"JCI Insight"},{"key":"400_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2024.1324393","volume":"15","author":"M Geng","year":"2024","unstructured":"Geng M, Liu W, Li J, Yang G, Tian Y, Jiang X, et al. LncRNA as a regulator in the development of diabetic complications. Front Endocrinol. 2024;15:1\u201313.","journal-title":"Front Endocrinol"},{"key":"400_CR12","doi-asserted-by":"crossref","unstructured":"Xu L, Natarajan R, Chen Z. Epigenetic risk profile of diabetic kidney disease in high-risk populations. Curr Diab Rep. 2019;19:9.","DOI":"10.1007\/s11892-019-1129-2"},{"key":"400_CR13","doi-asserted-by":"crossref","unstructured":"Han L, Kong R, Yin DD, Zhang EB, Xu TP, De W, et al. Low expression of long noncoding RNA GAS6-AS1 predicts a poor prognosis in patients with NSCLC. Med Oncol. 2013;30:694.","DOI":"10.1007\/s12032-013-0694-5"},{"key":"400_CR14","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1111\/jcmm.12431","volume":"18","author":"J Chen","year":"2014","unstructured":"Chen J, Wang R, Zhang K, Chen LB. Long non-coding RNAs in non-small cell lung cancer as biomarkers and therapeutic targets. J Cell Mol Med. 2014;18:2425\u201336.","journal-title":"J Cell Mol Med"},{"key":"400_CR15","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.cell.2018.03.052","volume":"173","author":"AC Bester","year":"2018","unstructured":"Bester AC, Lee JD, Chavez A, Lee YR, Nachmani D, Vora S, et al. An integrated genome-wide CRISPRa approach to functionalize lncRNAs in drug resistance. Cell. 2018;173:649\u201364.e20.","journal-title":"Cell"},{"key":"400_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biom11020301","volume":"11","author":"AAA El-Fattah","year":"2021","unstructured":"El-Fattah AAA, Sadik NAH, Shaker OG, Kamal AM, Shahin NN. Serum long non-coding RNAs PVT1, HOTAIR, and NEAT1 as potential biomarkers in Egyptian women with breast cancer. Biomolecules. 2021;11:1\u201319.","journal-title":"Biomolecules"},{"key":"400_CR17","unstructured":"Morris KV. Current topics in microbiology and immunology. In: Long non-coding RNAs in human disease. Springer Cham; 2025."},{"key":"400_CR18","doi-asserted-by":"crossref","unstructured":"Soremekun OS, Ezenwa C, Soliman M, Chikowore T, Nashiru O, Fatumo S. Transcription-translation error: in-silico investigation of the structural and functional impact of deleterious single nucleotide polymorphisms in GULP1 gene. Informatics Med Unlocked. 2021;22:100503.","DOI":"10.1016\/j.imu.2020.100503"},{"key":"400_CR19","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1097\/CM9.0000000000002673","volume":"136","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Chang D, Wu L, Yu X, Wang S, Zhao M, et al. Clinical and histopathological predictors of rapid kidney function decline in patients with biopsy-proven diabetic kidney disease. Chin Med J. 2023;136:1243\u20135.","journal-title":"Chin Med J"},{"key":"400_CR20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.diabres.2011.09.013","volume":"95","author":"CH Lee","year":"2012","unstructured":"Lee CH, Chu NF, Shieh YS, Hung YJ. The growth arrest-specific 6 (Gas6) gene polymorphism c.834+7G>A is associated with type 2 diabetes. Diabetes Res Clin Pract. 2012;95:201\u20136.","journal-title":"Diabetes Res Clin Pract"},{"key":"400_CR21","first-page":"00","volume":"44","author":"M \u00d6zel","year":"2022","unstructured":"\u00d6zel M, Ba\u015fkol G, Abedi AH, At\u0131c\u0131 Y, Sara\u00e7o\u011flu H, Sungur N, et al. Evaluation of serum growth arrest specific-6\/sAXL levels in type 2 diabetes mellitus. Erciyes Med J. 2022;44:00.","journal-title":"Erciyes Med J"},{"key":"400_CR22","doi-asserted-by":"publisher","first-page":"e35788","DOI":"10.1097\/MD.0000000000035788","volume":"102","author":"Y Xiong","year":"2023","unstructured":"Xiong Y, Wang B, Jiao J, Tang M, Li K, Jiang R, et al. Expression and clinical association of MFG-E8 and TAM receptors in diabetic patients with different stages of microvascular complication: an experimental study. Medicine. 2023;102:e35788.","journal-title":"Medicine"},{"key":"400_CR23","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1016\/j.numecd.2022.05.007","volume":"32","author":"H Fan","year":"2022","unstructured":"Fan H, Han J, Chen L, Feng B, Sun X, Shi B. Association between plasma growth arrest-specific protein 6 and carotid atherosclerosis in type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis. 2022;32:1917\u201323.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"400_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14814\/phy2.15825","volume":"11","author":"OP Nordb\u00f8","year":"2023","unstructured":"Nordb\u00f8 OP, Landolt L, Eikrem \u00d8, Scherer A, Leh S, Furriol J, et al. Transcriptomic analysis reveals partial epithelial\u2013mesenchymal transition and inflammation as common pathogenic mechanisms in hypertensive nephrosclerosis and type 2 diabetic nephropathy. Physiol Rep. 2023;11:1\u201319.","journal-title":"Physiol Rep"},{"key":"400_CR25","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.freeradbiomed.2019.01.046","volume":"134","author":"DQ Chen","year":"2019","unstructured":"Chen DQ, Feng YL, Chen L, Liu JR, Wang M, Vaziri ND, et al. Poricoic acid A enhances melatonin inhibition of AKI-to-CKD transition by regulating Gas6\/Axl\u2013NF\u2013\u03baB\/Nrf2 axis. Free Radic Biol Med. 2019;134:484\u201397.","journal-title":"Free Radic Biol Med"},{"key":"400_CR26","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.kint.2021.05.036","volume":"100","author":"K M\u00f6ller-Hackbarth","year":"2021","unstructured":"M\u00f6ller-Hackbarth K, Dabaghie D, Charrin E, Zambrano S, Genov\u00e9 G, Li X, et al. Retinoic acid receptor responder1 promotes development of glomerular diseases via the nuclear factor-\u03baB signaling pathway. Kidney Int. 2021;100:809\u201323.","journal-title":"Kidney Int"},{"key":"400_CR27","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jss.2015.05.049","volume":"199","author":"MD Giangola","year":"2015","unstructured":"Giangola MD, Yang WL, Rajayer SR, Kuncewitch M, Molmenti E, Nicastro J, et al. Growth arrest-specific protein 6 protects against renal ischemia-reperfusion injury. J Surg Res. 2015;199:572\u20139.","journal-title":"J Surg Res"},{"key":"400_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fchem.2023.1335330","volume":"11","author":"SU Rehman","year":"2024","unstructured":"Rehman SU, Ullah N, Zhang Z, Zhen Y, Din AU, Cui H, et al. Recent insights into the functions and mechanisms of antisense RNA: emerging applications in cancer therapy and precision medicine. Front Chem. 2024;11:1\u201318.","journal-title":"Front Chem"},{"key":"400_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gene.2018.12.079","volume":"696","author":"P Zhang","year":"2019","unstructured":"Zhang P, Dong Q, Zhu H, Li S, Shi L, Chen X. Long non-coding antisense RNA GAS6-AS1 supports gastric cancer progression via increasing GAS6 expression. Gene. 2019;696:1\u20139.","journal-title":"Gene"},{"key":"400_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.omtn.2021.04.022","volume":"25","author":"J Luo","year":"2021","unstructured":"Luo J, Wang H, Wang L, Wang G, Yao Y, Xie K, et al. lncRNA GAS6-AS1 inhibits progression and glucose metabolism reprogramming in LUAD via repressing E2F1-mediated transcription of GLUT1. Mol Ther Nucleic Acids. 2021;25:11\u201324.","journal-title":"Mol Ther Nucleic Acids"},{"key":"400_CR31","doi-asserted-by":"publisher","first-page":"11200","DOI":"10.1002\/jcp.27770","volume":"234","author":"S Huang","year":"2019","unstructured":"Huang S, Xu Y, Ge X, Xu B, Peng W, Jiang X, et al. Long noncoding RNA NEAT1 accelerates the proliferation and fibrosis in diabetic nephropathy through activating Akt\/mTOR signaling pathway. J Cell Physiol. 2019;234:11200\u20137.","journal-title":"J Cell Physiol"},{"key":"400_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13098-021-00725-5","volume":"13","author":"M Xiao","year":"2021","unstructured":"Xiao M, Bai S, Chen J, Li Y, Zhang S, Hu Z. CDKN2B-AS1 participates in high glucose-induced apoptosis and fibrosis via NOTCH2 through functioning as a miR-98-5p decoy in human podocytes and renal tubular cells. Diabetol Metab Syndr. 2021;13:1\u201312.","journal-title":"Diabetol Metab Syndr"},{"key":"400_CR33","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.neuint.2018.03.011","volume":"118","author":"Y Ma","year":"2018","unstructured":"Ma Y, Zhou G, Li M, Hu D, Zhang L, Liu P, et al. Long noncoding RNA DANCR mediates cisplatin resistance in glioma cells via activating AXL\/PI3K\/Akt\/NF-\u03baB signaling pathway. Neurochem Int. 2018;118:233\u201341.","journal-title":"Neurochem Int"},{"key":"400_CR34","doi-asserted-by":"publisher","first-page":"9232","DOI":"10.1073\/pnas.1102281108","volume":"108","author":"A D\u00e1valos","year":"2011","unstructured":"D\u00e1valos A, Goedeke L, Smibert P, Ram\u00edrez CM, Warrier NP, Andreo U, et al. miR-33a\/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc Natl Acad Sci USA. 2011;108:9232\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"400_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12882-016-0343-2","volume":"17","author":"Z Wang","year":"2016","unstructured":"Wang Z, Wang Z, Zhou Z, Ren Y. Crucial genes associated with diabetic nephropathy explored by microarray analysis. BMC Nephrol. 2016;17:1\u20137.","journal-title":"BMC Nephrol"},{"key":"400_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2196\/32437","volume":"3","author":"M Khokhar","year":"2022","unstructured":"Khokhar M, Roy D, Tomo S, Gadwal A, Sharma P, Purohit P. Novel molecular networks and regulatory microRNAs in type 2 diabetes mellitus: multiomics integration and interactomics study. JMIR Bioinform Biotechnol. 2022;3:1\u201324.","journal-title":"JMIR Bioinform Biotechnol"},{"key":"400_CR37","doi-asserted-by":"publisher","first-page":"499","DOI":"10.2478\/jomb-2018-0009","volume":"37","author":"IH Demirsoy","year":"2018","unstructured":"Demirsoy IH, Ertural DY, Balci \u015e, \u00c7lnklr \u00dc, Sezer K, Tamer L, et al. Profiles of circulating miRNAs following metformin treatment in patients with type 2 diabetes. J Med Biochem. 2018;37:499\u2013506.","journal-title":"J Med Biochem"},{"key":"400_CR38","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1007\/s00204-019-02586-4","volume":"93","author":"Y Liu","year":"2019","unstructured":"Liu Y, Duan C, Liu W, Chen X, Wang Y, Liu X, et al. Upregulation of let-7f-2-3p by long noncoding RNA NEAT1 inhibits XPO1-mediated HAX-1 nuclear export in both in vitro and in vivo rodent models of doxorubicin-induced cardiotoxicity. Arch Toxicol. 2019;93:3261\u201376.","journal-title":"Arch Toxicol"},{"key":"400_CR39","doi-asserted-by":"crossref","unstructured":"Li B, Zhao X, Xie W, Hong Z, Zhang Y. Integrative analyses of biomarkers and pathways for diabetic nephropathy. Front Genet. 2023;14:1128136.","DOI":"10.3389\/fgene.2023.1128136"},{"key":"400_CR40","doi-asserted-by":"publisher","first-page":"e1053","DOI":"10.1002\/iid3.1053","volume":"12","author":"X Zhuang","year":"2024","unstructured":"Zhuang X, Sun Z, Du H, Zhou T, Zou J, Fu W. Metformin inhibits high glucose-induced apoptosis of renal podocyte through regulating miR-34a\/SIRT1 axis. Immunity Inflamm Dis. 2024;12:e1053.","journal-title":"Immunity Inflamm Dis"},{"key":"400_CR41","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1177\/0960327120952157","volume":"40","author":"HJ Wang","year":"2021","unstructured":"Wang HJ, Liu H, Lin YH, Zhang SJ. MiR-32-5p knockdown inhibits epithelial to mesenchymal transition and renal fibrosis by targeting SMAD7 in diabetic nephropathy. Hum Exp Toxicol. 2021;40:587\u201395.","journal-title":"Hum Exp Toxicol"},{"key":"400_CR42","doi-asserted-by":"publisher","first-page":"6050874","DOI":"10.1155\/2020\/6050874","volume":"2020","author":"LP Wang","year":"2020","unstructured":"Wang LP, Geng JN, Sun B, Sun CB, Shi Y, Yu XY. MiR-92b-3p is induced by advanced glycation end products and involved in the pathogenesis of diabetic nephropathy. Evid Based Complement Alternat Med. 2020;2020:6050874.","journal-title":"Evid Based Complement Alternat Med"},{"key":"400_CR43","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1681\/ASN.2015091017","volume":"28","author":"Y Liu","year":"2017","unstructured":"Liu Y, Li H, Liu J, Han P, Li X, Bai H, et al. Variations in MicroRNA-25 expression influence the severity of diabetic kidney disease. J Am Soc Nephrol. 2017;28:3627\u201338.","journal-title":"J Am Soc Nephrol"},{"key":"400_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1157194","volume":"14","author":"DD Mishra","year":"2023","unstructured":"Mishra DD, Sahoo B, Maurya PK, Sharma R, Varughese S, Prasad N, et al. Therapeutic potential of urine exosomes derived from rats with diabetic kidney disease. Front Endocrinol. 2023;14:1157194.","journal-title":"Front Endocrinol"},{"key":"400_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/etm.2021.10985","volume":"23","author":"M Fawzy","year":"2021","unstructured":"Fawzy M, Al Ageeli E, Al\u2011Qahtani S, Abu Alsel B, Kattan S, Alelwani W, et al. MicroRNA\u2011499a (rs3746444A\/G) gene variant and susceptibility to type 2 diabetes\u2011associated end\u2011stage renal disease. Exp Ther Med. 2021;23:1\u20138.","journal-title":"Exp Ther Med"},{"key":"400_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40246-023-00457-9","volume":"17","author":"J Li","year":"2023","unstructured":"Li J, Liu D, Ren J, Li G, Zhao Z, Zhao H, et al. Integrated analysis of RNA methylation regulators crosstalk and immune infiltration for predictive and personalized therapy of diabetic nephropathy. Hum Genomics. 2023;17:1\u201319.","journal-title":"Hum Genomics"},{"key":"400_CR47","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2147\/DMSO.S240956","volume":"13","author":"L Shu","year":"2020","unstructured":"Shu L, Zhao H, Huang W, Hou G, Song G, Ma H. Resveratrol upregulates mmu-miR-363-3p via the Pi3K-Akt pathway to improve insulin resistance induced by a high-fat diet in mice. Diabetes Metab Syndr Obes. 2020;13:391\u2013403.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"400_CR48","first-page":"1619","volume":"44","author":"N Li","year":"2019","unstructured":"Li N, Wang LJ, Xu WL, Liu S, Yu JY. MicroRNA\u2011379\u20115p suppresses renal fibrosis by regulating the LIN28\/let\u20117 axis in diabetic nephropathy. Int J Mol Med. 2019;44:1619\u201328.","journal-title":"Int J Mol Med"},{"key":"400_CR49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-020-03229-8","volume":"12","author":"DW Liu","year":"2021","unstructured":"Liu DW, Liu FX, Li ZY, Pan SK, Xie JW, Zhao ZH, et al. HNRNPA1-mediated exosomal sorting of miR-483-5p out of renal tubular epithelial cells promotes the progression of diabetic nephropathy-induced renal interstitial fibrosis. Cell Death Dis. 2021;12:1\u201315.","journal-title":"Cell Death Dis"},{"key":"400_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-18649-4","volume":"8","author":"TC Messemaker","year":"2018","unstructured":"Messemaker TC, Van Leeuwen SM, Van Den Berg PR, Jong AEJT, Palstra RJ, Hoeben RC, et al. Allele-specific repression of SOX2 through the long non-coding RNA SOX2OT. Sci Rep. 2018;8:1\u201313.","journal-title":"Sci Rep"},{"key":"400_CR51","doi-asserted-by":"crossref","unstructured":"Chen K, Yu B, Liao J. LncRNA SOX2OT alleviates mesangial cell proliferation and fibrosis in diabetic nephropathy via Akt\/mTOR-mediated autophagy. Mol Med. 2021;27:71.","DOI":"10.1186\/s10020-021-00310-6"},{"key":"400_CR52","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/jcmm.13986","volume":"23","author":"X Rui","year":"2019","unstructured":"Rui X, Wang L, Pan H, Gu T, Shao S, Leng J. LncRNA GAS6-AS2 promotes bladder cancer proliferation and metastasis via GAS6-AS2\/miR-298\/CDK9 axis. J Cell Mol Med. 2019;23:865\u201376.","journal-title":"J Cell Mol Med"},{"key":"400_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm9072184","volume":"9","author":"I Sidorkiewicz","year":"2020","unstructured":"Sidorkiewicz I, Niemira M, Maliszewska K, Erol A, Bielska A, Szalkowska A, et al. Circulating mirnas as a predictive biomarker of the progression from prediabetes to diabetes: outcomes of a 5-year prospective observational study. J Clin Med. 2020;9:1\u201320.","journal-title":"J Clin Med"},{"key":"400_CR54","first-page":"4011","volume":"12","author":"C Liang","year":"2019","unstructured":"Liang C, Pang L, Ke Y, Ji W, Xiong J, Ding R, et al. LncRNA GAS6-AS2 facilitates tumor growth and metastasis of hepatocellular carcinoma by activating the PI3K\/AKT\/FoxO3a signaling pathway. Int J Clin Exp Pathol. 2019;12:4011\u201323.","journal-title":"Int J Clin Exp Pathol"},{"key":"400_CR55","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12041-022-01397-4","volume":"102","author":"L Jia","year":"2022","unstructured":"Jia L, Wang W, Liu H, Zhu F, Huang Y. LncRNA TTN-AS1 exacerbates extracellular matrix accumulation via miR-493-3p\/FOXP2 axis in diabetic nephropathy. J Genet. 2022;102:11.","journal-title":"J Genet"},{"key":"400_CR56","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1080\/0886022X.2022.2092001","volume":"44","author":"H Cui","year":"2022","unstructured":"Cui H, Ren G, Hu X, Xu B, Li Y, Niu Z, et al. Suppression of lncRNA GAS6-AS2 alleviates sepsis-related acute kidney injury through regulating the miR-136-5p\/OXSR1 axis in vitro and in vivo. Ren Fail. 2022;44:1071\u201383.","journal-title":"Ren Fail"},{"key":"400_CR57","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1166\/mex.2023.2424","volume":"13","author":"H Zhang","year":"2023","unstructured":"Zhang H, Liu Z, Li Q. Circ_0015756 modulates high glucose-induced podocyte injury through miR-136 in diabetic nephropathy. Mater Express. 2023;13:806\u201314.","journal-title":"Mater Express"},{"key":"400_CR58","doi-asserted-by":"crossref","unstructured":"Yadav M, Sharma A, Patne K, Tabasum S, Suryavanshi J, Rawat L, et al. AXL signaling in cancer: from molecular insights to targeted therapies. Signal Transduct Target Ther. 2025;10:37.","DOI":"10.1038\/s41392-024-02121-7"},{"key":"400_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2024.1446672","volume":"15","author":"SM Gr\u00f8ndal","year":"2024","unstructured":"Gr\u00f8ndal SM, Bl\u00f8 M, Nilsson LIH, Rayford AJ, Jackson A, Gausdal G, et al. Targeting AXL cellular networks in kidney fibrosis. Front Immunol. 2024;15:1\u201312.","journal-title":"Front Immunol"},{"key":"400_CR60","doi-asserted-by":"crossref","unstructured":"Tanaka M, Siemann DW. Therapeutic targeting of the Gas6\/Axl signaling pathway in cancer. Int J Mol Sci. 2021;22:9953.","DOI":"10.3390\/ijms22189953"}],"container-title":["Nutrition &amp; Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41387-025-00400-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41387-025-00400-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41387-025-00400-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T14:03:50Z","timestamp":1763647430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41387-025-00400-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["400"],"URL":"https:\/\/doi.org\/10.1038\/s41387-025-00400-y","relation":{},"ISSN":["2044-4052"],"issn-type":[{"value":"2044-4052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"19 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}